

Steroidal Glycosides from *Agave utahensis* and Their Cytotoxic ActivityAkihito Yokosuka,^{*,†} Maki Jitsuno,[†] Satoru Yui,[‡] Masatoshi Yamazaki,[‡] and Yoshihiro Mimaki^{*,†}*Laboratory of Medicinal Pharmacognosy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Horinouchi 1432-1, Hachioji, Tokyo 192-0392, Japan, and Faculty of Pharmaceutical Sciences, Teikyo University, Suarashi 1091-1, Sagamiko, Tsukui-gun, Kanagawa 199-0195, Japan*

Received March 13, 2009

Eight new spirostanol saponins (**1–8**) and three new furostanol saponins (**9–11**) were isolated from the whole plants of *Agave utahensis*. The structures of **1–11** were determined by analysis of extensive spectroscopic data. The saponins were evaluated for their cytotoxic activity against HL-60 human promyelocytic leukemia cells. Compound **1** showed cytotoxicity against HL-60 cells with an IC₅₀ value of 4.9 μg/mL, induced apoptosis in HL-60 cells, and markedly activated caspase-3.

Agave utahensis Engelm. (Agavaceae) is native to South and Central America. The leaves of this plant are roasted and eaten, and the fiber has various uses.¹ Previously, we reported four new steroidal glycosides, based on (25*R*)-5α-spirostan-3β,6α-diol (chlorogenin) as the aglycone, from the whole plants of *A. utahensis*.² Further phytochemical analysis of the saponin-enriched fraction prepared from the MeOH extract of this plant has resulted in the isolation and structure determination of eight new spirostanol saponins (**1–8**) and three new furostanol saponins (**9–11**). The cytotoxic activity of **1–11** against HL-60 human promyelocytic leukemia cells and the apoptosis induction properties of saponin (**1**) for HL-60 cells are also reported.

Results and Discussion

Fresh whole plants of *A. utahensis* (2.5 kg) were extracted with MeOH. After removal of solvent, the crude extract was fractionated by repeated column chromatography (CC) on porous-polymer polystyrene resin (Diaion HP-20), silica gel, and octadecylsilanized (ODS) silica gel to yield **1–11**.

Compound **1** was obtained as an amorphous solid with the molecular formula C₃₉H₆₄O₁₃ from its HRESITOFMS (*m/z* 741.4417 [M + H]⁺) and ¹³C NMR data. The ¹H NMR spectrum showed signals for two anomeric protons at δ 5.27 (d, *J* = 7.9 Hz) and 4.78 (d, *J* = 7.7 Hz), along with signals for four methyl groups at δ 1.15 (d, *J* = 6.9 Hz), 0.82 (s), 0.82 (s), and 0.70 (d, *J* = 5.6 Hz). Acid hydrolysis of **1** with 1 M HCl in dioxane–H₂O (1:1) yielded a saponin identified as (25*R*)-5β-spirostan-3β-ol (smilagenin: **1a**),³ D-galactose, and D-glucose. Identification of the monosaccharides was carried out by direct HPLC analysis of the hydrolysate, using a combination of refractive index (RI) and optical rotation (OR) detectors. The above data, along with anomeric carbon signals at δ 107.1 and 103.7, suggested that **1** was a smilagenin diglycoside. Analysis of the NMR data implied that the sugar moiety of **1** was composed of a β-D-galactopyranosyl (⁴C₁) unit (Gal) and a β-D-glucopyranosyl (⁴C₁) unit (Glc) (Table 1). The glucosyl residue was the terminal unit, as indicated by the absence of any glycosylation shift for its carbon resonances (Table 2).^{3,4} In the HMBC spectrum of **1**, the anomeric proton (H-1) of Glc at δ 5.27 showed a long-range correlation with C-4 of Gal at δ 80.1, of which H-1 at δ 4.78 in turn showed an HMBC correlation with C-3 of the aglycone at δ 74.7. Thus, **1** was determined to be (25*R*)-5β-spirostan-3β-yl *O*-β-D-glucopyranosyl-(1→4)-β-D-galactopyranoside.

Compound **2** was obtained as an amorphous solid, C₃₉H₆₄O₁₃, by HRESITOFMS (*m/z* 741.4417 [M + H]⁺). Acid hydrolysis of **2** gave **1a**, D-galactose, and D-glucose. The ¹H and ¹³C NMR spectra of **1** and **2** were similar; however the terminal β-D-glucopyranosyl unit was attached to C-3 of the inner β-D-galactopyranosyl unit [δ_{H} 4.88 (d, *J* = 7.7 Hz); δ_{C} 103.2, 71.8, 85.1, 70.0, 76.7, and 62.4] instead of C-4 of Gal. In the HMBC spectrum of **2**, long-range correlations were observed between H-1 of Glc and C-3 of Gal and between H-1 of Gal and C-3 of the aglycone. Thus, **2** was formulated as (25*R*)-5β-spirostan-3β-yl *O*-β-D-glucopyranosyl-(1→3)-β-D-galactopyranoside.

Compound **3** analyzed for C₄₅H₇₄O₁₈ by HRESITOFMS (*m/z* 903.4917 [M + H]⁺), higher than that of **1** by C₆H₁₀O₅, and the ¹H NMR spectrum showed signals for three anomeric protons (δ 5.20, 5.14, and 4.80). Acid hydrolysis of **3** yielded **1a**, D-glucose, and D-galactose. Comparison of the ¹³C NMR spectrum of **3** with that of **1** showed a set of six additional signals corresponding to a terminal β-D-glucopyranosyl moiety (Glc', see Table 2), and the signal due to C-2 of the glucose moiety linked to C-4 of the inner galactosyl moiety and its neighboring carbons varied, while all other signals remained almost unaffected. In the HMBC spectrum of **3**, long-range correlations were observed between H-1 of Glc' and C-2 of Glc, between H-1 of Glc and C-4 of Gal, and between H-1 of Gal and C-3 of the aglycone. Compound **3** was thus (25*R*)-5β-spirostan-3β-yl *O*-β-D-glucopyranosyl-(1→2)-*O*-β-D-glucopyranosyl-(1→4)-β-D-galactopyranoside.

Compound **4** had the molecular formula C₃₉H₆₂O₁₄ (HRESITOFMS). Analysis of the ¹³C NMR spectrum of **4** and comparison with that of **1** revealed that **4** possessed a diglycoside moiety identical to that of **1**, but differed slightly from **1** in the aglycone structure. The IR (1707 cm⁻¹) and the ¹³C NMR (δ 213.0) spectra demonstrated that the aglycone contained a carbonyl group and that it was located at C-12 by HMBC correlations between C-12 (δ 213.0) and H₂-11 (δ 2.37) and δ 2.21 (dd, *J* = 14.0, 4.9 Hz)/H-17 at δ 2.82 (dd, *J* = 8.6, 6.8 Hz)/Me-18 at δ 1.09 (s). Acid hydrolysis of **4** gave (25*R*)-3β-hydroxy-5β-spirostan-12-one (**4a**),⁵ D-galactose, and D-glucose. Thus, **4** was determined to be (25*R*)-3β-[(*O*-β-D-glucopyranosyl-(1→4)-β-D-galactopyranosyl)oxy]-5β-spirostan-12-one.


Compound **5** (C₃₉H₆₂O₁₄) furnished **4a**, D-galactose, and D-glucose, when **5** was subjected to acid hydrolysis. The ¹H and ¹³C NMR spectra of **5** indicated that the diglycoside attached to C-3 of the aglycone was the same as that of **2**. Thus, compound **5** was (25*R*)-3β-[(*O*-β-D-glucopyranosyl-(1→3)-β-D-galactopyranosyl)oxy]-5β-spirostan-12-one.

Compound **6** had the molecular formula C₃₉H₆₄O₁₄ (HRESITOFMS), which was higher than that of **1** by one oxygen atom. The spectroscopic properties of **6** were similar to those of **1**, except

* To whom correspondence should be addressed. Tel: +81-42-676-4577. Fax: +81-42-676-4579. E-mail: yokosuka@toyaku.ac.jp; mimakiy@toyaku.ac.jp.

[†] Tokyo University of Pharmacy and Life Sciences.

[‡] Teikyo University.



for differences between the carbon signals attributed to ring A (C-1–C-4). Acid hydrolysis of **6** gave an aglycone, identified as (25*R*)-5β-spirost-2β,3β-diol (**6a**),⁶ together with D-galactose and D-glucose. The structure of **6** was thus characterized as (25*R*)-2β-hydroxy-5β-spirostan-3β-yl *O*-β-D-glucopyranosyl-(1→4)-β-D-galactopyranoside.

Compound **7** (C₄₅H₇₄O₁₉) gave **6a**, D-galactose, and D-glucose on acid hydrolysis. Analysis of the ¹H–¹H COSY, HMQC, and HMBC spectra of **7** indicated that the sugar moiety of **7** comprised a terminal β-D-glucopyranosyl unit, a 2-substituted β-D-glucopyranosyl unit, and a 4-substituted β-D-galactopyranosyl unit and that their sequence is the same as that of **3**. The structure of **7** was determined to be (25*R*)-2β-hydroxy-5β-spirostan-3β-yl *O*-β-D-glucopyranosyl-(1→2)-*O*-β-D-glucopyranosyl-(1→4)-β-D-galactopyranoside.

Compound **8** (C₄₅H₇₄O₁₉) gave **6a**, D-galactose, and D-glucose on acid hydrolysis. Comparison of the ¹H and ¹³C NMR spectra of **8** with those of **7** showed their structural similarity, except for the triglycoside moiety linked to C-3 of the aglycone. The ¹H–¹H COSY and HMQC spectra indicated that the triglycoside moiety of **8** included a C-2 and C-4 disubstituted β-D-galactopyranosyl unit [δ_H 4.91 (d, *J* = 7.6 Hz); δ_C 102.7, 81.8, 75.0, 79.0, 75.6, and 60.7] and two terminal β-D-glucopyranosyl units (Glc and Glc'). In the HMBC spectrum of **8**, long-range correlations were observed between H-1 of Glc' at δ 5.23 and C-4 of Gal at δ 79.0, between H-1 of Glc at δ 5.24 and C-2 of Gal at δ 81.8, and between H-1 of Gal at δ 4.91 and C-3 of the aglycone at δ 81.4. The structure of **8** was assigned as (25*R*)-2β-hydroxy-5β-spirostan-3β-yl *O*-β-D-glucopyranosyl-(1→2)-*O*-[β-D-glucopyranosyl-(1→4)]-β-D-galactopyranoside.

Compound **9** (C₄₆H₇₈O₁₉) was shown to be a 22-methoxyfurostanol saponin by Ehrlich's test,^{7,8} and by ¹H NMR [δ 3.28 (3H, s)] and ¹³C NMR [δ 112.6 (C-22) and 47.3 (Me)] spectra.⁹ The ¹H NMR spectrum of **9** showed signals for three anomeric protons at δ 5.28 (1H, d, *J* = 7.9 Hz), 4.85 (1H, d, *J* = 7.8 Hz), and 4.79 (1H, d, *J* = 7.7 Hz), as well as signals for four steroid methyl groups at δ 1.21 (d, *J* = 6.9 Hz), 1.01 (d, *J* = 6.6 Hz), 0.83 (s), and 0.81 (s). Enzymatic hydrolysis of **9** with β-D-glucosidase gave **1** and D-glucose. An NOE correlation from the methoxy signal at δ 3.28 to the H-16 signal at δ 4.52 (m) was consistent with the C-22α configuration. Thus, the structure of **9** was determined to be (25*R*)-26-[(β-D-glucopyranosyl)oxy]-22α-methoxy-5β-furostan-3β-yl *O*-β-D-glucopyranosyl-(1→4)-β-D-galactopyranoside.

Compound **10** (C₅₂H₈₈O₂₄) was suggested to be the corresponding 22-methoxyfurostanol saponin of **3** with a glucosyl unit at C-26. Enzymatic hydrolysis of **10** with β-D-glucosidase afforded **3** and D-glucose. The structure of **10** was thus (25*R*)-26-[(β-D-glucopyranosyl)oxy]-22α-methoxy-5β-furostan-3β-yl *O*-β-D-glucopyranosyl-(1→2)-*O*-β-D-glucopyranosyl-(1→4)-β-D-galactopyranoside.

Compound **11** (C₅₈H₉₈O₂₉) showed spectral features closely related to those of **10**. However, the molecular formula of **11** was higher than that of **10** by C₆H₁₀O₅, and the ¹H NMR spectrum showed signals for five anomeric protons. On comparison of the ¹³C NMR spectrum of **11** with that of **10**, six signals corresponding to a terminal β-D-glucopyranosyl moiety (Glc''') were observed at δ 105.4 (CH), 75.2 (CH), 78.4 (CH), 71.6 (CH), 78.4 (CH), and 62.7 (CH₂), and the signal due to C-6 of the glucosyl moiety (Glc'') attached at C-26 of the aglycone was shifted downfield by 7.2 ppm in **11**. In the HMBC spectrum of **11**, a long-range correlation was observed between H-1 of Glc''' at δ 5.11 and C-6 of Glc'' at δ 70.1 and between H-1 of Glc'' at δ 4.77 and C-26 of the aglycone at δ 75.3. Accordingly, the structure of **11** was formulated as (25*R*)-26-[(*O*-β-D-glucopyranosyl-(1→6)-β-D-glucopyranosyl)oxy]-22α-methoxy-5β-furostan-3β-yl *O*-β-D-glucopyranosyl-(1→2)-*O*-β-D-glucopyranosyl-(1→4)-β-D-galactopyranoside.

Compounds **1–11** were evaluated for their cytotoxic activity against HL-60 leukemia cells using a modified MTT assay method. Compounds **1–3** were cytotoxic against HL-60 cells with IC₅₀ values of 4.9, 7.0, and 4.9 μg/mL, respectively, whereas **4–11** exhibited no apparent cytotoxicity at sample concentrations of 10 μg/mL. The above results indicate that the C-2 hydroxy group and the C-12 carbonyl group significantly reduce cytotoxic

Table 1. ¹H NMR Chemical Shift Assignments for the Sugar Moieties of Compounds **1–11** in C₅D₅N^a

position		1	2	3	4	5	6
Gal	1	4.78 d (7.7)	4.88 d (7.7)	4.80 d (7.8)	4.76 d (7.7)	4.85 d (7.7)	4.86 d (7.8)
	2	4.39 dd (9.4, 7.7)	4.65 dd (9.7, 7.7)	4.57 dd (9.8, 7.8)	4.39 dd (9.5, 7.7)	4.64 dd (9.8, 7.7)	4.47 dd (8.8, 7.8)
	3	4.21 dd (9.4, 3.2)	4.30 dd (9.7, 2.9)	4.07 dd (9.8, 3.3)	4.20 dd (9.5, 3.2)	4.29 dd (9.8, 3.2)	4.23 dd (8.8, 3.1)
	4	4.70 br d (3.2)	4.76 br d (2.9)	4.56 br d (3.3)	4.69 br d (3.2)	4.76 br d (3.2)	4.68 br d (3.1)
	5	4.02 m	4.04 m	3.96 m	4.00 m	4.02 m	4.09 m
	6	a 4.66 dd (10.6, 8.8) b 4.22 m	4.41 m 4.36 m	4.73 dd (9.9, 9.9) 4.19 dd (9.9, 5.1)	4.65 dd (10.6, 8.6) 4.20 m	4.37 m 4.35 dd (10.9, 5.6)	4.65 dd (10.5, 8.7) 4.26 m
Glc	1	5.27 d (7.9)	5.45 d (7.8)	5.14 d (7.8)	5.27 d (7.9)	5.44 d (7.8)	5.28 d (7.9)
	2	4.12 dd (8.5, 7.9)	4.04 m	4.11 dd (8.7, 7.8)	4.13 dd (8.9, 7.9)	4.04 m	4.14 dd (9.0, 7.9)
	3	4.22 dd (8.5, 8.5)	4.26 m	4.26 dd (8.7, 8.7)	4.23 dd (8.9, 8.9)	4.26 m	4.24 dd (9.0, 9.0)
	4	4.06 dd (8.5, 8.5)	4.26 m	3.97 m	4.07 dd (8.9, 8.9)	4.27 m	4.09 dd (9.0, 9.0)
	5	4.01 m	3.99 m	3.97 m	4.01 m	3.98 m	4.02 m
	6	a 4.60 dd (11.1, 2.4) b 4.20 m	4.52 dd (11.6, 2.2) 4.42 m	4.62 m 4.11 m	4.60 dd (11.1, 2.4) 4.21 m	4.52 br d (11.6) 4.40 dd (11.6, 5.4)	4.61 m 4.22 m
Glc'	1			5.20 d (7.6)			
	2			4.04 dd (9.1, 7.6)			
	3			4.11 dd (9.1, 9.1)			
	4			4.20 dd (9.1, 9.1)			
	5			3.77 m			
	6	a 4.59 m b 4.37 dd (12.3, 3.5)					
Glc''	1						
	2						
	3						
	4						
	5						
	6	a b					
Glc'''	1						
	2						
	3						
	4						
	5						
	6	a b					

position		7	8	9	10	11
Gal	1	4.88 d (7.9)	4.91 d (7.6)	4.79 d (7.7)	4.80 d (7.7)	4.80 d (7.7)
	2	4.65 dd (10.0, 7.9)	4.63 dd (9.2, 7.6)	4.40 m	4.57 m	4.57 dd (8.9, 7.7)
	3	4.08 dd (10.0, 3.0)	4.31 dd (9.2, 3.1)	4.22 m	4.07 m	4.07 dd (8.9, 3.3)
	4	4.56 br d (3.0)	4.66 br d (3.1)	4.70 br d (3.2)	4.57 br d (3.3)	4.57 br d (3.3)
	5	4.24 m	4.04 m	4.04 m	3.96 m	3.98 m
	6	a 4.72 dd (9.9, 9.9) b 4.23 dd (9.9, 5.4)	4.56 m 4.23 m	4.67 dd (10.1, 9.0) 4.24 m	4.73 dd (10.5, 9.8) 4.19 dd (10.5, 5.5)	4.73 dd (10.1, 9.8) 4.19 m
Glc	1	5.15 d (7.8)	5.24 d (7.7)	5.28 d (7.9)	5.14 d (7.8)	5.14 d (7.8)
	2	4.10 dd (8.6, 7.8)	4.06 dd (8.8, 7.7)	4.13 dd (8.3, 7.9)	4.11 dd (8.9, 7.8)	4.11 dd (8.9, 7.8)
	3	4.26 dd (8.6, 8.6)	4.16 dd (8.8, 8.8)	4.23 m	4.26 dd (8.9, 8.9)	4.26 dd (8.9, 8.9)
	4	3.97 dd (8.6, 8.6)	4.26 dd (8.8, 8.8)	4.07 dd (9.5, 9.5)	3.96 dd (8.9, 8.9)	3.96 m
	5	3.96 m	3.79 m	4.02 m	3.97 m	3.96 m
	6	a 4.62 m b 4.10 m	4.49 dd (11.4, 2.2) 4.41 dd (11.4, 4.5)	4.61 dd (11.4, 2.1) 4.22 m	4.56 dd (9.2, 2.7) 4.10 m	4.63 br d (11.0) 4.11 m
Glc'	1	5.25 d (7.6)	5.23 d (7.7)	4.85 d (7.8)	5.20 d (7.5)	5.20 d (7.6)
	2	4.62 dd (8.6, 7.6)	4.11 dd (8.6, 7.7)	4.04 m	4.04 dd (8.9, 7.5)	4.05 dd (8.9, 7.6)
	3	4.14 dd (9.3, 8.6)	4.22 dd (9.2, 8.6)	4.24 m	4.11 dd (8.9, 8.9)	4.11 dd (8.9, 8.9)
	4	4.19 dd (9.3, 9.3)	4.09 dd (9.2, 9.2)	4.23 m	4.20 dd (8.9, 8.9)	4.21 dd (9.3, 8.9)
	5	3.89 m	3.97 m	3.97 m	3.78 m	3.78 m
	6	a 4.64 m b 4.42 dd (12.3, 3.8)	4.57 m 4.22 m	4.57 dd (12.0, 2.3) 4.41 m	4.60 dd (12.0, 2.3) 4.37 dd (12.0, 3.4)	4.60 m 4.37 m
Glc''	1				4.85 d (7.8)	4.77 d (7.8)
	2				4.04 dd (9.0, 7.8)	3.98 dd (8.4, 7.8)
	3				4.25 dd (9.0, 9.0)	4.19 dd (8.4, 8.4)
	4				4.22 dd (9.0, 9.0)	4.16 dd (9.0, 8.4)
	5				3.96 m	4.08 m
	6	a 4.63 m b 4.39 dd (11.9, 5.4)			4.63 m 4.39 dd (11.9, 5.4)	4.84 m 4.34 m
Glc'''	1					5.11 d (7.7)
	2					4.47 dd (9.1, 7.7)
	3					4.22 dd (9.1, 9.1)
	4					4.24 dd (9.1, 9.1)
	5					3.93 m
	6	a 4.51 br d (9.1) b 4.37 m				4.51 br d (9.1) 4.37 m

^a Values in parentheses are coupling constants in Hz.

activity in these 5β -spirostanol glycosides. The morphological observation (data not shown) suggested that HL-60 cell death caused by **1** and **3** is mediated partially through induction of

apoptosis. In agarose gel electrophoresis of DNA, a typical ladder pattern of the internucleosomal fragmentation of DNA was observed when HL-60 cells were treated with 20 $\mu\text{g/mL}$ of **1**

Table 2. ^{13}C NMR Chemical Shift Assignments for Compounds **1–11** in $\text{C}_5\text{D}_5\text{N}$

position	1	2	3	4	5	6	7	8	9	10	11
1	30.9	30.9	30.8	30.4	30.3	40.5	40.5	40.5	30.8	30.9	30.8
2	27.0	27.0	27.0	26.7	26.7	66.8	66.9	67.1	27.0	27.0	27.0
3	74.7	74.4	74.7	74.3	74.0	80.2	79.7	81.4	74.7	74.7	74.8
4	30.6	30.5	30.7	30.6	30.6	31.9	32.0	31.5	30.6	30.6	30.7
5	36.9	36.9	36.9	36.5	36.5	36.4	36.4	36.4	36.9	36.9	36.9
6	27.0	27.0	27.0	26.7	26.8	26.1	26.2	26.2	27.0	27.0	27.0
7	26.7	26.8	26.7	26.3	26.4	26.7	26.7	26.8	26.7	26.7	26.7
8	35.5	35.6	35.5	34.7	34.7	35.5	35.5	35.6	35.5	35.5	35.5
9	40.2	40.2	40.2	41.9	41.9	41.3	41.4	41.4	40.2	40.2	40.2
10	35.2	35.2	35.2	35.6	35.7	36.9	36.9	37.0	35.2	35.2	35.2
11	21.1	21.2	21.1	37.7	37.8	21.3	21.3	21.3	21.1	21.1	21.1
12	40.3	40.3	40.3	213.0	213.0	40.2	40.2	40.2	40.2	40.1	40.1
13	40.9	40.9	40.9	55.6	55.6	40.8	40.8	40.8	41.2	41.2	41.2
14	56.4	56.5	56.5	56.0	56.0	56.3	56.3	56.3	56.4	56.4	56.4
15	32.2	32.2	32.1	31.4	31.5	32.1	32.1	32.1	32.1	32.1	32.1
16	81.2	81.3	81.2	79.8	79.8	81.2	81.2	81.2	81.4	81.4	81.4
17	63.1	63.1	63.1	54.3	54.3	63.1	63.1	63.1	64.4	64.4	64.5
18	16.6	16.6	16.6	16.0	16.1	16.5	16.5	16.5	16.5	16.5	16.5
19	23.8	23.9	23.9	23.0	23.0	23.7	23.8	23.9	23.8	23.8	23.9
20	42.0	42.0	42.0	42.6	42.7	42.0	42.0	42.0	40.5	40.5	40.6
21	15.0	15.1	15.0	13.9	13.9	15.0	15.0	15.0	16.3	16.3	16.4
22	109.2	109.2	109.2	109.3	109.3	109.2	109.2	109.2	112.6	112.6	112.6
23	31.8	31.9	31.8	31.8	31.8	31.8	31.8	31.9	30.8	30.8	30.8
24	29.2	29.3	29.2	29.2	29.2	29.3	29.2	29.3	28.2	28.2	28.2
25	30.6	30.6	30.6	30.5	30.5	30.6	30.6	30.6	34.2	34.2	34.1
26	66.9	66.9	66.9	66.9	67.0	66.9	66.9	66.9	75.2	75.2	75.3
27	17.3	17.3	17.3	17.3	17.3	17.3	17.3	17.3	17.1	17.1	17.1
OMe									47.3	47.3	47.3
Gal	1	103.7	103.2	103.4	103.6	103.1	104.6	104.2	102.7	103.7	103.4
	2	73.5	71.8	73.2	73.5	71.7	72.8	72.4	81.8	73.5	73.2
	3	75.2	85.1	75.6	75.2	85.1	75.1	75.4	75.0	75.2	75.6
	4	80.1	70.0	80.9	80.1	69.9	80.0	80.9	79.0	80.1	81.0
	5	75.3	76.7	75.0	75.4	76.7	75.8	75.5	75.6	75.4	75.0
	6	60.9	62.4	60.5	60.9	62.4	60.8	60.4	60.7	60.9	60.5
Glc	1	107.1	106.7	105.0	107.1	106.7	107.2	105.0	105.6	107.1	105.0
	2	75.9	75.9	86.3	75.9	75.9	75.9	86.2	76.8	75.9	86.3
	3	78.7	78.4	78.5	78.7	78.4	78.7	78.5	78.0	78.7	78.5
	4	72.3	71.5	71.8	72.3	71.5	72.2	71.7	71.9	72.3	71.7
	5	78.5	78.7	78.1	78.5	78.7	78.5	78.2	78.3	78.5	78.1
	6	63.1	62.6	63.2	63.1	62.6	63.1	63.2	62.9	63.1	63.2
Glc'	1			107.0				106.9	106.9	105.0	107.0
	2			76.6				76.5	75.9	75.2	76.6
	3			77.7				77.9	78.6	78.6	77.7
	4			70.2				70.3	72.2	71.8	70.2
	5			79.0				79.0	78.5	78.5	79.0
	6			61.5				61.7	63.1	62.9	61.5
Glc''	1										104.9
	2										75.2
	3										78.6
	4										71.7
	5										78.5
	6										62.9
Glc'''	1										105.4
	2										75.2
	3										78.4
	4										71.6
	5										78.4
	6										62.7

for 18 h (Figure 1). Caspases are cysteine proteases and play essential roles in the apoptotic signaling pathway. Among caspases, caspase-3 has been shown to be the executing enzyme of apoptosis. Caspase-3 was markedly activated when HL-60 cells were treated with **1** and **3** at sample concentrations of 20 $\mu\text{g}/\text{mL}$ for 6 h (Figure 2). Although the structure of **2** is very similar to that of **1**, **2** did not induce apoptosis in HL-60 cells.

Experimental Section

General Experimental Procedures. Optical rotations were measured using a JASCO DIP-360 automatic digital polarimeter. IR spectra were recorded on a JASCO FT-IR 620 spectrophotometer. NMR spectra were recorded on a Bruker DRX-500 spectrophotometer using standard Bruker pulse programs. Chemical shifts are given as δ values with

reference to tetramethylsilane (TMS) as an internal standard. HRES-ITOFMS were recorded on a Waters-Micromass LCT mass spectrometer. Diaion HP-20 (Mitsubishi-Chemical, Tokyo, Japan), silica gel (Fuji-Silysia Chemical, Aichi, Japan), and ODS silica gel (Nacalai Tesque, Kyoto, Japan) were used for CC. TLC was carried out on precoated Kieselgel 60 F₂₅₄ (0.25 mm, Merck) and RP₁₈ F₂₅₄ S (0.25 mm, Merck) plates, and spots were visualized by spraying the plates with 10% H₂SO₄ solution, followed by heating. HPLC was performed by using a system composed of a CCPM pump (Tosoh, Tokyo, Japan), a CCP PX-8010 controller (Tosoh), an RI-8010 (Tosoh) or a Shodex OR-2 (Showa-Denko, Tokyo, Japan) detector, and a Rheodyne injection port. HL-60 cells were obtained from the Human Science Research Resources Bank (JCRB 0085, Osaka, Japan). The following reagents were obtained from the indicated companies: RPMI 1640 medium and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)




Figure 1. Induction of DNA fragmentation by **1** in HL-60 cells. HL-60 cells were incubated at 37 °C for 18 h with 0, 10, or 20 $\mu\text{g/mL}$ of **1** or 10 $\mu\text{g/mL}$ of etoposide (E). DNA was then extracted and applied to agarose gel electrophoresis. M: DNA marker.




Figure 2. Caspase-3 activity in **1**, **2**, **3**, or etoposide-treated HL-60 cell lysates. HL-60 cells were incubated at 37 °C for 6 h with 0, 10, or 20 $\mu\text{g/mL}$ of **1**, **2**, or **3**, or 10 $\mu\text{g/mL}$ of etoposide (E). Each value represents mean \pm SE from triplicate determinations.

(Sigma-Aldrich, St. Louis, MO); FBS (Bio-Whittaker, Walkersville, MO); penicillin G sodium salt and streptomycin sulfate (Gibco, Grand Island, NY). All other chemicals used were of biochemical reagent grade.

Plant Material. *A. utahensis* plants were purchased from a garden center at Japan Cactus Planning Co. (Fukushima, Japan) in 2000 and identified by Dr. Yutaka Sashida, emeritus professor of the Tokyo University of Pharmacy and Life Sciences. A voucher specimen has been deposited in our laboratory (voucher no. AU-2000-001, Laboratory of Medicinal Pharmacognosy).

Extraction and Isolation. The plant material (2.5 kg) was extracted with hot MeOH twice (each 6 L). The MeOH extract was concentrated under reduced pressure, and the concentrate (190 g) was passed through a Diaion HP-20 column, successively eluted with 30% MeOH, 50% MeOH, MeOH, EtOH, and EtOAc (each 4 L). The MeOH eluate was chromatographed on silica gel and eluted with a stepwise gradient of CHCl_3 –MeOH (9:1; 4:1; 3:1; 2:1; 1:1) and finally with MeOH alone, yielding fractions (I–V). Fraction II was chromatographed on silica gel eluted with CHCl_3 –MeOH– H_2O (60:10:1; 50:10:1) and ODS silica gel with MeOH– H_2O (8:3; 4:1) and CH_3CN – H_2O (5:7) to give **1** (150 mg), **2** (14 mg), **3** (820 mg), **4** (13 mg), **5** (4.5 mg), **6** (78 mg), **7** (12 mg), **8** (8.5 mg), and **9** (50 mg). Fraction IV was subjected to CC on silica gel eluted with CHCl_3 –MeOH– H_2O (20:10:1; 7:4:1) and ODS silica gel with MeOH– H_2O (2:1; 4:1) and CH_3CN – H_2O (1:2; 1:3) to give **10** (42 mg) and **11** (7.0 mg). The furostanol saponins **9** and **11** were obtained as mixtures of C-22 methoxy and C-22 hydroxy forms. The C-22 hydroxy form was converted to the C-22 methoxy form by treatment with hot MeOH, and the structure elucidation was carried out with the C-22 methoxy form.

Compound 1: amorphous solid; $[\alpha]_{\text{D}}^{28}$ -48.0 (*c* 0.10; MeOH); IR (film) ν_{max} 3347 (OH), 2926 (CH), 1058 cm^{-1} ; ^1H NMR (500 MHz, $\text{C}_5\text{D}_5\text{N}$) δ 4.63 (1H, m, H-16), 4.31 (1H, br s, H-3), 1.15 (3H, d, *J* = 6.9 Hz, Me-21), 0.82 (3H, s, Me-19), 0.82 (3H, s, Me-18), 0.70 (3H, d, *J* = 5.6 Hz, Me-27), signals for the sugar moiety, see Table 1; ^{13}C NMR, see Table 2; HRESITOFMS *m/z* 741.4417 [*M* + *H*] $^+$ (calcd for $\text{C}_{39}\text{H}_{65}\text{O}_{13}$, 741.4425).

Acid Hydrolysis of 1. A solution of **1** (9.7 mg) in 1 M HCl (dioxane– H_2O , 1:1; 2 mL) was heated at 95 °C for 2 h under an Ar atmosphere. After cooling, the reaction mixture was neutralized by

passage through an Amberlite IRA-93ZU column and was chromatographed on silica gel eluted with CHCl_3 –MeOH (9:1) to yield **1a** (3.0 mg) and a sugar fraction (4.2 mg). The sugar fraction was passed through a Sep-Pak C_{18} cartridge and a Toyopak IC-SP M cartridge, which was then analyzed by HPLC under the following conditions: column, Capcell Pak NH2 UG80 (4.6 mm i.d. \times 250 mm, 5 μm , Shiseido, Tokyo, Japan); solvent, MeCN– H_2O (17:3); flow rate, 0.9 mL/min; detection, RI and OR. Identification of D-galactose and D-glucose present in the sugar fraction was carried out by comparison of their retention times and specific optical rotations with those of authentic samples.

Compound 2: amorphous solid; $[\alpha]_{\text{D}}^{28}$ -10.0 (*c* 0.10; MeOH); IR (film) ν_{max} 3363 (OH), 2927 (CH), 1075 cm^{-1} ; ^1H NMR (500 MHz, $\text{C}_5\text{D}_5\text{N}$) δ 4.62 (1H, m, H-16), 4.37 (1H, br s, H-3), 1.16 (3H, d, *J* = 6.9 Hz, Me-21), 0.85 (3H, s, Me-19), 0.83 (3H, s, Me-18), 0.70 (3H, d, *J* = 5.3 Hz, Me-27), signals for the sugar moiety, see Table 1; ^{13}C NMR, see Table 2; HRESITOFMS *m/z* 741.4417 [*M* + *H*] $^+$ (calcd for $\text{C}_{39}\text{H}_{65}\text{O}_{13}$, 741.4425).

Compound 3: amorphous solid; $[\alpha]_{\text{D}}^{28}$ -44.0 (*c* 0.10; MeOH); IR (film) ν_{max} 3376 (OH), 2928 (CH), 1072 cm^{-1} ; ^1H NMR (500 MHz, $\text{C}_5\text{D}_5\text{N}$) δ 4.61 (1H, m, H-16), 4.32 (1H, br s, H-3), 1.15 (3H, d, *J* = 6.9 Hz, Me-21), 0.87 (3H, s, Me-19), 0.82 (3H, s, Me-18), 0.69 (3H, d, *J* = 5.5 Hz, Me-27), signals for the sugar moiety, see Table 1; ^{13}C NMR, see Table 2; HRESITOFMS *m/z* 903.4917 [*M* + *H*] $^+$ (calcd for $\text{C}_{45}\text{H}_{75}\text{O}_{18}$, 903.4953).

Compound 4: amorphous solid; $[\alpha]_{\text{D}}^{28}$ -10.0 (*c* 0.10; MeOH); IR (film) ν_{max} 3376 (OH), 2926 (CH), 1707 (C=O), 1074, 1030 cm^{-1} ; ^1H NMR (500 MHz, $\text{C}_5\text{D}_5\text{N}$) δ 4.55 (1H, m, H-16), 4.27 (1H, br s, H-3), 2.82 (1H, dd, *J* = 8.6, 6.8 Hz, H-17), 2.37 (1H, dd, *J* = 14.0, 14.0 Hz, H-11a), 2.21 (1H, dd, *J* = 14.0, 4.9 Hz, H-11b), 1.37 (3H, d, *J* = 6.9 Hz, Me-21), 1.09 (3H, s, Me-18), 0.83 (3H, s, Me-19), 0.70 (3H, d, *J* = 5.9 Hz, Me-27), signals for the sugar moiety, see Table 1; ^{13}C NMR, see Table 2; HRESITOFMS *m/z* 777.3985 [*M* + *Na*] $^+$ (calcd for $\text{C}_{39}\text{H}_{62}\text{O}_{14}\text{Na}$, 777.4037).

Compound 5: amorphous solid; $[\alpha]_{\text{D}}^{24}$ -4.0 (*c* 0.10; MeOH); IR (film) ν_{max} 3356 (OH), 2927 (CH), 1707 (C=O), 1074 cm^{-1} ; ^1H NMR (500 MHz, $\text{C}_5\text{D}_5\text{N}$) δ 4.55 (1H, m, H-16), 4.31 (1H, br s, H-3), 2.83 (1H, br t, *J* = 7.8 Hz, H-17), 2.37 (1H, dd, *J* = 13.8, 13.8 Hz, H-11a), 2.20 (1H, dd, *J* = 13.8, 4.7 Hz, H-11b), 1.37 (3H, d, *J* = 6.9 Hz, Me-21), 1.09 (3H, s, Me-18), 0.85 (3H, s, Me-19), 0.70 (3H, d, *J* = 5.5 Hz, Me-27), signals for the sugar moiety, see Table 1; ^{13}C NMR, see Table 2; HRESITOFMS *m/z* 777.3981 [*M* + *Na*] $^+$ (calcd for $\text{C}_{39}\text{H}_{62}\text{O}_{14}\text{Na}$, 777.4037).

Compound 6: amorphous solid; $[\alpha]_{\text{D}}^{24}$ -52.0 (*c* 0.10; MeOH); IR (film) ν_{max} 3346 (OH), 2929 (CH), 1055 cm^{-1} ; ^1H NMR (500 MHz, $\text{C}_5\text{D}_5\text{N}$) δ 4.60 (1H, m, H-16), 4.42 (1H, br s, H-3), 3.87 (1H, br d, *J* = 12.7 Hz, H-2), 1.14 (3H, d, *J* = 6.9 Hz, Me-21), 0.84 (3H, s, Me-19), 0.81 (3H, s, Me-18), 0.70 (3H, d, *J* = 5.5 Hz, Me-27), signals for the sugar moiety, see Table 1; ^{13}C NMR, see Table 2; HRESITOFMS *m/z* 757.4426 [*M* + *H*] $^+$ (calcd for $\text{C}_{39}\text{H}_{65}\text{O}_{14}$, 757.4374).

Compound 7: amorphous solid; $[\alpha]_{\text{D}}^{25}$ -34.0 (*c* 0.10; MeOH); IR (film) ν_{max} 3348 (OH), 2926 (CH), 1073 cm^{-1} ; ^1H NMR (500 MHz, $\text{C}_5\text{D}_5\text{N}$) δ 4.59 (1H, m, H-16), 4.46 (1H, br s, H-3), 3.88 (1H, m, H-2), 1.13 (3H, d, *J* = 6.9 Hz, Me-21), 0.90 (3H, s, Me-19), 0.80 (3H, s, Me-18), 0.69 (3H, d, *J* = 5.5 Hz, Me-27), signals for the sugar moiety, see Table 1; ^{13}C NMR, see Table 2; HRESITOFMS *m/z* 941.4734 [*M* + *Na*] $^+$ (calcd for $\text{C}_{45}\text{H}_{74}\text{O}_{19}\text{Na}$, 941.4722).

Compound 8: amorphous solid; $[\alpha]_{\text{D}}^{25}$ -2.0 (*c* 0.10; MeOH); IR (film) ν_{max} 3375 (OH), 2928 (CH), 1074 cm^{-1} ; ^1H NMR (500 MHz, $\text{C}_5\text{D}_5\text{N}$) δ 4.61 (1H, m, H-16), 4.34 (1H, br s, H-3), 3.82 (1H, br d, *J* = 12.8 Hz, H-2), 1.14 (3H, d, *J* = 6.8 Hz, Me-21), 0.99 (3H, s, Me-19), 0.82 (3H, s, Me-18), 0.70 (3H, d, *J* = 4.9 Hz, Me-27), signals for the sugar moiety, see Table 1; ^{13}C NMR, see Table 2; HRESITOFMS *m/z* 941.4689 [*M* + *Na*] $^+$ (calcd for $\text{C}_{45}\text{H}_{74}\text{O}_{19}\text{Na}$, 941.4722).

Acid Hydrolysis of 2–8. Compounds **2** (7.0 mg), **3** (10 mg), **4** (13 mg), **5** (4.6 mg), **6** (10 mg), **7** (10 mg), and **8** (6.0 mg) were independently subjected to acid hydrolysis as described for **1** to give aglycones (**1a**: 3.5 and 2.9 mg from **2** and **3**, **4a**: 7.0 and 1.7 mg from **4** and **5**, **6a**: 4.0, 4.8, and 2.4 mg from **6**, **7**, and **8**, respectively) and a sugar fractions (**2**: 2.6 mg, **3**: 4.3 mg, **4**: 5.0 mg, **5**: 1.6 mg, **6**: 3.8 mg, **7**: 4.1 mg, **8**: 3.3 mg). HPLC analysis of the sugar fractions under the same conditions as in the case of **1** showed the presence of D-galactose and D-glucose in those of **2–8**.

Compound 9: amorphous solid; $[\alpha]_{\text{D}}^{23}$ -36.0 (*c* 0.10; MeOH); IR (film) ν_{max} 3364 (OH), 2929 (CH), 1069 cm^{-1} ; ^1H NMR (500 MHz,

C₅D₅N) δ 4.52 (1H, m, H-16), 4.31 (1H, br s, H-3), 3.28 (3H, s, OMe), 1.21 (3H, d, $J = 6.9$ Hz, Me-21), 1.01 (3H, d, $J = 6.6$ Hz, Me-27), 0.83 (3H, s, Me-19), 0.81 (3H, s, Me-18), signals for the sugar moieties, see Table 1; ¹³C NMR, see Table 2; HRESITOFMS m/z 957.5071 [M + Na]⁺ (calcd for C₄₆H₇₈O₁₉Na, 957.5035).

Enzymatic Hydrolysis of 9. Compound **9** (9.3 mg) was treated with β -D-glucosidase (6.0 mg) in HOAc/NaOAc buffer (pH 5.0, 10 mL) at room temperature for 12 h. The reaction mixture was chromatographed on silica gel eluted with CHCl₃-MeOH-H₂O (20:10:1) to yield **1** (3.0 mg) and D-glucose (1.0 mg).

Compound 10: amorphous solid; [α]_D²⁸ -50.0 (c 0.10; MeOH); IR (film) ν_{\max} 3375 (OH), 2927 (CH), 1084, 1029 cm⁻¹; ¹H NMR (500 MHz, C₅D₅N) δ 4.52 (1H, m, H-16), 4.32 (1H, br s, H-3), 3.27 (3H, s, OMe), 1.20 (3H, d, $J = 6.9$ Hz, Me-21), 1.00 (3H, d, $J = 6.6$ Hz, Me-27), 0.87 (3H, s, Me-19), 0.79 (3H, s, Me-18), signals for the sugar moieties, see Table 1; ¹³C NMR, see Table 2; HRESITOFMS m/z 1119.5522 [M + Na]⁺ (calcd for C₅₂H₈₈O₂₄Na, 1119.5563).

Enzymatic Hydrolysis of 10. Compound **10** (11 mg) was treated with β -D-glucosidase (12 mg) as described for **9** to yield **3** (9.0 mg) and D-glucose (1.0 mg).

Compound 11: amorphous solid; [α]_D²⁸ -22.0 (c 0.10; MeOH); IR (film) ν_{\max} 3376 (OH), 2927 (CH), 1084, 1029 cm⁻¹; ¹H NMR (500 MHz, C₅D₅N) δ 4.51 (1H, m, H-16), 4.31 (1H, br s, H-3), 3.27 (3H, s, OMe), 1.20 (3H, d, $J = 6.8$ Hz, Me-21), 1.00 (3H, d, $J = 6.4$ Hz, Me-27), 0.87 (3H, s, Me-19), 0.80 (3H, s, Me-18), signals for the sugar moieties, see Table 1; ¹³C NMR, see Table 2; HRESITOFMS m/z 1281.6122 [M + Na]⁺ (calcd for C₅₈H₉₈O₂₉Na, 1281.6091).

HL-60 Cell Culture Assay. HL-60 cells were maintained in RPMI 1640 medium containing heat-inactivated 10% (v/v) fetal bovine serum (FBS) supplemented with 100 units/mL penicillin G sodium salt and 100 μ g/mL streptomycin sulfate. For cytotoxicity assay, the cells were washed and resuspended in the above medium to 4×10^4 cells/mL, and 196 μ L of this cell suspension was placed in each well of a 96-well flat-bottom plate. The cells were incubated in a humidified air/CO₂ (19:1) atmosphere for 24 h at 37 °C. After incubation, 4 μ L of EtOH-H₂O (1:1) solution containing the sample was added to give the final concentrations of 0.1–10 μ g/mL; 4 μ L of EtOH-H₂O (1:1) was added into control wells. The cells were further incubated for 72 h in the presence of each agent. Then cell growth was evaluated by the modified MTT assay procedure established by Sargent and Taylor.⁹ A dose-response curve was plotted for **1–3**, which showed less than 50% of cell growth at the sample concentration of 10 μ g/mL, and the concentration giving 50% inhibition (IC₅₀) was calculated. Each assay was done in triplicate.

Assay for Detection of DNA Fragmentation. The cells were incubated at 37 °C for 18 h with varying the concentrations of test samples. DNA was extracted with a commercially available kit (Wizard Genomic DNA Purification Kit, Promega, WI). In brief, cells (2×10^6 cells) were centrifuged for 5 min at 10000g. The cell pellet was resuspended in 600 μ L of nuclei lysis solution. Then, 3 μ L of 4 mg/

mL RNaseA solution was added to the cell lysate, and the solution was incubated at 37 °C for 15 min. Protein precipitation solution (200 μ L) was added into the RNaseA-treated cell lysate, and the mixture was incubated for 5 min on ice and centrifuged at 10000g for 5 min. The supernatant was transferred to a clean 1.5 mL microcentrifuged tube containing 600 μ L of 2-propanol and mixed by inversion. After centrifugation at 10000g for 5 min, DNA was visible as a small white pellet, and it was washed with 70% EtOH. Finally, the pellet was resuspended in 25 μ L of DNA rehydration solution and incubated at 65 °C for 1 h, which was stored at -20 °C until use. The sample (10–15 μ L) was applied to 2% agarose gel electrophoresis in 40 mM Tris-acetate buffer (pH 7.4) at 50 V for 1 h. DNA molecular weight marker (pH marker, Takara, Shiga, Japan) and DNA from apoptotic HL-60 cells induced by 10 μ g/mL etoposide were used for calibration. The DNA fragmentation pattern was examined in photographs taken under UV illumination.

Assay for Caspase-3 Activation. The activity of caspase-3 was measured using a commercially available kit (APPOCYTO Caspase-3 Colorimetric Assay Kit, MBL, Aichi, Japan). HL-60 cells (2×10^6) were treated with test samples for 6 h, and the cells were centrifuged and collected. Cell pellets were suspended in 60 μ L of ice cold cell lysis buffer and incubated on ice for 10 min. This cell pellet suspension was centrifuged at 10000g for 5 min, and the supernatant was collected. The cell lysate (50 μ L, equivalent to 200 μ g of protein) was mixed with 50 μ L of 2 \times reaction buffer containing the substrates for caspase-3 (DEVD-pNA (*p*-nitroanilide)). After incubation for 2 h at 37 °C, the absorbance at 405 nm of the liberated chromophore pNA was measured using a microplate reader. The activity of caspase-3 was evaluated in triplicate.

Supporting Information Available: ¹H NMR chemical shift assignments for the aglycone moieties of **1–11**. This information is available free of charge via the Internet at <http://pubs.acs.org>.

References and Notes

- Irish, M.; Irish, G. *Agaves, Yuccas, and Related Plants*; Timber Press: Portland, OR, 2000; pp 174–176.
- Yokosuka, A.; Mimaki, Y. *Chem. Pharm. Bull.* **2007**, *55*, 145–149.
- Agrawal, P. K.; Jain, D. C.; Gupta, R. K.; Thakur, R. S. *Phytochemistry* **1985**, *24*, 2479–2496.
- Agrawal, P. K. *Phytochemistry* **1992**, *31*, 3307–3330.
- Nakano, K.; Midzuta, Y.; Hara, Y.; Murakami, K.; Takaishi, Y.; Tomimatsu, T. *Phytochemistry* **1991**, *30*, 633–636.
- Nakano, K.; Yamasaki, T.; Imamura, Y.; Murakami, K.; Takaishi, Y.; Tomimatsu, T. *Phytochemistry* **1989**, *28*, 1215–1217.
- Kiyosawa, S.; Hutoh, M.; Komori, T.; Nohara, T.; Hosokawa, I.; Kawasaki, T. *Chem. Pharm. Bull.* **1968**, *16*, 1162–1164.
- Nohara, T.; Miyahara, K.; Kawasaki, T. *Chem. Pharm. Bull.* **1975**, *23*, 872–885.
- Sargent, J. M.; Taylor, C. G. *Br. J. Cancer* **1989**, *60*, 206–210.

NP900168D